Genmab Shares Jump as Rina-S Shows Durable Ovarian Cancer Responses in Phase 2 Trial
Genmab shares jumped more than 4% on Monday after the Danish biotechnology company reported encouraging Phase 2 data for Rina-S, its experimental ovarian cancer treatment.
The drug produced clinically meaningful and durable responses in patients with platinum-resistant ovarian cancer, a difficult-to-treat form of the disease. The results are significant because they provide Genmab with additional clinical evidence as it advances Rina-S into a broader Phase 3 development program.
The market reaction reflects the potential value of the drug, but investors should distinguish promising mid-stage trial results from regulatory approval or commercial success. Rina-S remains investigational.
Rina-S Delivers a 45.9% Response Rate
The latest data came from Part C of the Phase 1/2 RAINFOL-01 trial, presented at the International Gynecologic Cancer Society Congress in Montreal.
Among 109 treated patients with platinum-resistant ovarian cancer, Rina-S produced a confirmed objective response rate of 45.9%. That means cancer showed a predefined reduction in measurable tumour burden in nearly half of the patients assessed.
The result included five complete responses, meaning no detectable cancer was observed under the trial's response criteria.
Even more important for investors was the durability of those responses. The median duration of response was 12.1 months, while 51% of patients who responded were still responding one year later. Median progression-free survival was 9.5 months.
Progression-free survival, or PFS, measures how long patients live without their cancer worsening or dying from any cause. It is an important measure in oncology trials because a treatment that shrinks tumours but provides only a short-lived benefit may have limited clinical value.
Why the Patient Population Matters
The trial results are notable partly because the patients were heavily pretreated.
Genmab said 53% of the patients had already received three or four previous lines of treatment. All patients had previously received bevacizumab and a taxane, while 33% had received mirvetuximab soravtansine.
Platinum-resistant ovarian cancer is particularly challenging because the disease returns or progresses despite platinum-based chemotherapy.
A response rate approaching 46% in such a population can therefore be commercially and clinically meaningful if the results are reproduced in larger controlled trials.
However, the RAINFOL-01 study is not the same as a randomized Phase 3 trial. That distinction is important. Later-stage trials will need to establish whether the treatment's benefits hold up against appropriate comparison groups and translate into outcomes regulators consider sufficient for approval.
Rina-S Shows Activity Across FRα Expression Levels
Another potentially important feature of the data is the drug's activity across different levels of folate receptor alpha (FRα) expression.
Rina-S is designed as an FRα-targeted antibody-drug conjugate, or ADC. An ADC combines an antibody that targets a particular protein with a cancer-killing drug, allowing the therapy to deliver its payload toward cells carrying the target.
Genmab said antitumour activity was observed regardless of FRα expression, including in patients with low expression or no expression, and regardless of whether patients had previously received mirvetuximab.
If confirmed in later trials, broader activity could potentially expand the number of patients eligible for treatment.
That possibility is one reason investors are paying attention to the data beyond the headline response rate.
Safety Profile Will Also Matter
Positive efficacy data are only one side of a biotechnology investment case.
Genmab reported that common side effects included fatigue, nausea, anemia and neutropenia. Serious adverse events occurred in about one-third of participants, while 5.5% discontinued treatment because of adverse events. The company said it observed no safety signals for ocular toxicity, peripheral neuropathy, interstitial lung disease or stomatitis.
The safety profile will remain important as the number of patients increases in Phase 3 studies.
A drug can demonstrate strong efficacy but still face commercial or regulatory challenges if adverse events limit how frequently it can be administered or which patients can receive it.
For now, the reported data provide encouraging evidence, but longer and larger studies will offer a more reliable assessment.
Why Rina-S Matters to Genmab
Rina-S is becoming an increasingly important part of Genmab's pipeline.
The company is currently evaluating the drug in multiple Phase 3 studies covering platinum-resistant ovarian cancer, endometrial cancer and platinum-sensitive ovarian cancer settings. Genmab is also developing Rina-S in additional cancer types, including non-small cell lung cancer and gastrointestinal cancers.
That gives the program several potential commercial opportunities if clinical development succeeds.
The company already has an established oncology business, meaning Rina-S is being developed within a broader commercial platform rather than by a small biotechnology company dependent on a single experimental asset.
Still, pipeline success cannot be assumed. Each indication and trial has its own regulatory and clinical risks.
The Market Is Looking Beyond One Trial
Genmab's shares have been sensitive to pipeline developments because investors are assessing how the company's next generation of medicines can complement its existing portfolio.
The company reported strong first-half 2026 performance, with revenue rising 25% year on year and its full-year outlook raised, according to its recent earnings update.
That means the investment case is not dependent entirely on Rina-S.
But successful late-stage development could strengthen Genmab's long-term growth profile, particularly if Rina-S eventually receives regulatory approval across multiple indications.
The latest data therefore improve the clinical case for the drug, but they do not yet establish its ultimate commercial value.
Phase 3 Trials Are the Next Major Test
The most important next step is the ongoing Phase 3 development program.
Genmab's RAINFOL-02 trial is evaluating Rina-S against investigator's choice in patients with platinum-resistant ovarian cancer, with progression-free survival as a primary endpoint. Additional Phase 3 trials are examining endometrial cancer and platinum-sensitive ovarian cancer.
These studies should provide much stronger evidence about whether Rina-S can become a new treatment option.
For investors, Phase 3 execution may ultimately matter more than the current share-price reaction.
Positive Phase 2 data can increase expectations quickly, but biotechnology valuations can also reverse sharply if later-stage trials fail to reproduce earlier results.
Key Risks for Genmab Investors
Several risks remain despite the encouraging announcement.
Clinical risk: Phase 2 results do not guarantee positive Phase 3 outcomes.
Regulatory risk: Even strong trial data must meet regulatory requirements before commercial approval.
Safety risk: Adverse events can become more apparent as larger patient populations receive a drug.
Competition: Ovarian cancer has an expanding pipeline of targeted therapies and antibody-drug conjugates, increasing the competitive pressure on future treatments.
Valuation risk: A strong clinical announcement can raise expectations quickly, potentially leaving the stock sensitive to future trial results.
Investors should therefore avoid treating the share-price jump as confirmation that Rina-S will become a successful commercial product.
What Investors Should Watch Next
The key developments will include:
Progress in Rina-S Phase 3 trials
Comparative progression-free survival results
Overall survival data where applicable
Longer-term safety results
Regulatory interactions and potential filing plans
Expansion into additional cancer indications
Genmab's broader pipeline progress
The company's spending on late-stage development and launch preparation
The market will likely become increasingly focused on whether the Phase 2 signal can be reproduced in randomized studies.
Conclusion
Genmab's latest Rina-S results provide a meaningful boost to the company's ovarian cancer pipeline. In 109 heavily pretreated patients with platinum-resistant ovarian cancer, the drug generated a 45.9% confirmed response rate, a 12.1-month median duration of response and 9.5 months of median progression-free survival.
The durability of the responses and activity across different FRα expression levels are particularly encouraging. They help explain why Genmab shares rose more than 4% following the announcement.
But the investment story is now moving into a more demanding phase. The key question is whether Rina-S can reproduce these results in Phase 3 trials and ultimately secure regulatory approval.
For investors, the next major catalyst is therefore not simply another early-stage data release, but evidence that the promising Phase 2 results can translate into a successful late-stage treatment.
Follow our blog for more biotechnology, healthcare stocks, global markets and business updates.
This article is for informational and educational purposes only and should not be considered investment advice.